This company has pioneered the inhibition of CaMKII, a key player in cardiac function, marking a significant advancement in cardiovascular disease treatment by being the first to take a CaMKII inhibitor into a Phase 1 clinical trial in Q3 2022. This innovation opens avenues for rapid development in treating rare arrhythmias and broader cardiovascular diseases, including heart failure. Additionally, the company is exploring PDE9 inhibition as a foundational treatment for chronic heart failure, aiming to surpass existing treatments like Entresto with a next-generation neurohumoral drug. Through acquiring, discovering, and innovating, the company is at the forefront of transforming cardiovascular disease management.

Register for Details

For more details on financing and valuation for Cardurion Pharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Cardurion Pharma

Forge green plus iconForge green minus icon

What is Cardurion Pharma's IPO price?

The IPO price for Cardurion Pharma will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Cardurion Pharma?

Cardurion Pharma is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Cardurion Pharma shares pre-IPO?

If you own Cardurion Pharma pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Cardurion Pharma a publicly traded company?

Cardurion Pharma is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

What is Cardurion Pharma's funding to date?

Cardurion Pharma has raised $366.93MM to date.
Forge green plus iconForge green minus icon

When was Cardurion Pharma founded?

Cardurion Pharma was founded in 2017.

Cardurion Pharma Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
10/27/2021 Series A-1, A-2, A-3, A-4 and A-5 $366.93MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Apr 20, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.